Sarcomatrix Therapeutics Extends Investor Round to October 31

RENO, Nevada, Oct. 01, 2026 /CourierPR/ -- Sarcomatrix Therapeutics Corp., a preclinical-stage company based in Reno, Nevada, has extended the closing date of its accredited investor round from September 30, 2026, to October 31, 2026. The round is conducted under Regulation D, Rule 506(c), and remains available through the Investors section of the company’s website. The offering runs on the KoreConX platform, with KoreTransfer USA LLC acting as the transfer agent. All other terms of the offering are unchanged.

The extension gives prospective investors who are currently completing diligence and accredited investor verification time to finish that process before the round closes. Sarcomatrix is a company developing novel, first-in-class treatments for rare muscle-wasting diseases, including Duchenne muscular dystrophy, Becker muscular dystrophy, and limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

Since the round opened, Sarcomatrix has strengthened its governance and brought outside expertise to its lead program. Two independent directors, Brian Cain and Bill Ashton, have joined the Board of Directors, as the company announced on September 11, 2026. The company has selected the sulfate salt form of S-969 for development and has engaged specialist vendors for drug substance and drug product manufacturing. An independent regulatory and development consultancy is reviewing the regulatory, nonclinical, manufacturing, and first-in-human strategy for S-969 and for LAM-111, the company’s second program. An Orphan Drug Designation application for S-969 is in preparation, with LAM-111 holding Orphan Drug Designation in both the United States and the European Union.

The company has updated the development timeline stated in its July 24, 2026 release. The next major step toward human testing is contracting the provider for the Good Laboratory Practice (GLP) safety studies that regulators require before a drug can be given to people. The company currently expects the work required to reach an application to begin human testing to take approximately 12 months from the date that contract is signed. The target dates for a regulatory filing in the first quarter of 2027 and first-in-human dosing in the second quarter of 2027 stated in the July 24 release are superseded by this timeline. These are plans, not guarantees, and drug development frequently takes longer than expected or fails outright.

The company’s lead drug, S-969, is an oral, mutation-agnostic small molecule designed to upregulate alpha-7 beta-1 integrin, strengthening muscle-cell membranes and supporting muscle repair and regeneration. Because this approach does not depend on which genetic mutation a patient carries, it is designed to be relevant across the patient population rather than a single subgroup. S-969 is being developed for Duchenne muscular dystrophy, Becker muscular dystrophy, and LGMD2I/R9.

Sarcomatrix Therapeutics Corp. is a Delaware corporation headquartered in Reno, Nevada, and holds its programs under a worldwide exclusive license through the Nevada Research and Innovation Corporation. The company is developing novel, first-in-class treatments for rare muscle-wasting diseases, including Duchenne muscular dystrophy, Becker muscular dystrophy, LGMD2I/R9, and LAMA2-related congenital muscular dystrophy.

The extension of the accredited investor round to October 31, 2026, gives investors more time to complete the verification process, while the company continues to advance its lead drug, S-969, toward safety studies and eventual human testing. Sarcomatrix Therapeutics Corp. is a preclinical-stage company in the health-medicine sector, focusing on the development of treatments for rare muscle-wasting diseases.